ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 277 filers reported holding ROYALTY PHARMA PLC in Q1 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $44,751,255 | -1.3% | 1,648,904 | +11.7% | 0.01% | 0.0% |
| Q2 2023 | $45,359,606 | -10.6% | 1,475,589 | +4.8% | 0.01% | -13.3% |
| Q1 2023 | $50,713,558 | -5.7% | 1,407,537 | +3.4% | 0.02% | -11.8% |
| Q4 2022 | $53,793,794 | +4.8% | 1,361,179 | +6.6% | 0.02% | -5.6% |
| Q3 2022 | $51,322,000 | +4.6% | 1,277,283 | +9.4% | 0.02% | +5.9% |
| Q2 2022 | $49,073,000 | +17.2% | 1,167,285 | +8.6% | 0.02% | +30.8% |
| Q1 2022 | $41,860,000 | +6.3% | 1,074,421 | +8.7% | 0.01% | +8.3% |
| Q4 2021 | $39,375,000 | +15.2% | 988,086 | +4.4% | 0.01% | +9.1% |
| Q3 2021 | $34,192,000 | +213.8% | 946,099 | +255.9% | 0.01% | +175.0% |
| Q2 2021 | $10,897,000 | +1.9% | 265,825 | +8.4% | 0.00% | 0.0% |
| Q1 2021 | $10,693,000 | +18.4% | 245,137 | +35.8% | 0.00% | 0.0% |
| Q4 2020 | $9,035,000 | -0.0% | 180,501 | -16.0% | 0.00% | 0.0% |
| Q3 2020 | $9,039,000 | +15.2% | 214,855 | +32.9% | 0.00% | 0.0% |
| Q2 2020 | $7,849,000 | – | 161,667 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Siguler Guff Advisers, LLC | 3,391,754 | $122,204,897 | 47.65% |
| Vantage Consulting Group Inc | 1,022,194 | $36,829,650 | 20.91% |
| Indie Asset Partners, LLC | 433,000 | $15,600,990 | 18.22% |
| Overbrook Management Corp | 578,783 | $20,853,551 | 5.46% |
| Silicon Valley Community Foundation | 1,032,320 | $37,194,490 | 5.36% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,047,049 | $109,785,175 | 4.64% |
| Geo Capital Gestora de Recursos Ltd | 142,748 | $5,143 | 3.81% |
| Renaissance Capital LLC | 123,913 | $4,464,585 | 3.31% |
| Rokos Capital Management LLP | 1,106,813 | $40,077,698 | 2.96% |
| Lagoda Investment Management, L.P. | 101,500 | $3,657,045 | 2.60% |